Sight Sciences Sets New Fee Schedule for TearCare System
MENLO PARK, Calif. — Sight Sciences, Inc. (Nasdaq: SGHT), a leading eyecare technology company dedicated to innovative solutions that improve patient outcomes, has recently announced that two Medicare Administrative Contractors (MACs) have set a fee schedule for the TearCare System. This initiative is a significant advancement aimed at enhancing the accessibility of interventional treatments for patients suffering from dry eye conditions.
Collaboration with Medicare Administrative Contractors
The established pricing was made in partnership with Novitas Solutions, Inc. and First Coast Service Options, Inc., which have jurisdiction-wide pricing for the CPT code 0563T. This code refers to a vital procedure that enables the evacuation of meibomian glands using heat through innovative wearable devices. As of January 1, 2025, this fee schedule will be effective across all areas administered by these MACs, allowing for improved treatment accessibility.
Pleased to Support Eyecare Providers
Paul Badawi, Co-Founder and CEO of Sight Sciences, expressed gratitude towards the eyecare providers and relevant stakeholders for their collaborative efforts in establishing this pricing. He stated, "We are pleased that the rigorous review conducted by Novitas and First Coast resulted in a set fee structure. This ensures that Medicare beneficiaries have easier access to this crucial interventional dry eye treatment when deemed necessary by their healthcare providers."
Significance of the Established Fee Schedule
The local fee schedule outlined for CPT code 0563T will allow for improved claim processing in the jurisdictions covered by Novitas and FCSO. With approximately 10.4 million individuals benefiting from Medicare coverage in these regions, this new pricing aids in addressing the needs of approximately 30% of the total Medicare fee-for-service covered lives.
What Does This Mean for Patients?
With the TearCare procedures now incorporated within the pricing framework, eligible patients can receive necessary treatments based on their individual medical requirements. This structured approach not only supports quality treatment but also streamlines the reimbursement process for providers.
Launch of the Sight Access Portal
To further support the delivery of care, Sight Sciences has introduced the Sight Access Portal. This resource is designed to assist providers utilizing the TearCare System as well as the OMNI® Surgical System and SION® Surgical Instrument. The portal offers a comprehensive range of services, including patient benefit verifications, prior authorization assistance, and help with reimbursement inquiries.
Financial Guidance for 2025
Looking ahead, Sight Sciences aims to provide updated revenue and adjusted operating expenses guidance during its forthcoming earnings calls. This guidance will reflect the positive impacts of the new fee schedule and the company’s ongoing initiatives aimed at improving patient care.
About Sight Sciences
Established with a mission to transform eyecare, Sight Sciences is developing groundbreaking and minimally invasive technologies designed to treat prevalent eye diseases effectively. The TearCare System, recognized for its innovative solutions, is 510(k) cleared in the United States and is pivotal in addressing evaporative dry eye disease by providing localized heat therapy.
Contact Information
For media inquiries, please contact: pr@sightsciences.com.
For investor relations, reach out to Philip Taylor at Gilmartin Group at 415.937.5406 or via email at Investor.Relations@Sightsciences.com.
Frequently Asked Questions
What is the TearCare System?
The TearCare System is an innovative device designed to treat evaporative dry eye disease through localized heat therapy to unblock meibomian glands.
When will the new Medicare pricing take effect?
The new Medicare fee schedule for the TearCare System will be effective starting January 1, 2025.
What does CPT code 0563T represent?
CPT code 0563T refers to the evacuation of meibomian glands using heat and manual expression, applicable to the TearCare procedure.
How does the Sight Access Portal assist providers?
The Sight Access Portal provides support for patient benefit verifications, prior authorizations, and reimbursement questions for providers using the TearCare System and related technologies.
What is the significance of this pricing announcement?
This pricing allows easier access to the TearCare procedure for Medicare beneficiaries, enhancing treatment availability when deemed medically necessary by their eyecare providers.
